Scleroderma is an autoimmune condition that affects the skin, internal organs and blood vessels, causing scarring and thickening of the tissue in these areas. There are 2 main types of scleroderma: ...

Please provide your email address to receive an email when new articles are posted on . The classically defined diffuse subtype of juvenile systemic sclerosis demonstrates more globally severe disease ...

Daval International today announced positive results from its Double-Blind Placebo-Controlled Phase II Clinical Study evaluating the safety and tolerability of AIMSPRO given as a monotherapy to ...

SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc., announced today the online publication (ahead of print) of the findings from the STAR I trial in Arthritis & Rheumatology Journal, the official journal of ...

Each year 29 June marks World Scleroderma Day. This article highlights the symptoms, latest research and a genuine ‘diary’ experience from a US patient. The date 29 June was chosen to raise awareness ...

(MENAFN- GlobeNewsWire - Nasdaq) The diffuse cutaneous systemic sclerosis market landscape is evolving from conventional symptom-focused strategies toward therapies that specifically target fibrosis ...

"Diffuse Cutaneous Systemic Sclerosis Pipeline"As per DelveInsight's assessment, globally, Diffuse Cutaneous Systemic Sclerosis pipeline constitutes 15+ key companies continuously working towards ...

Diffuse systemic sclerosis (dSSc) can be a devastating disease, and to date there are no clearly beneficial treatments. However, the agent relaxin has shown some promise in improving skin disease. [1] ...

On August 19, 2015, Corbus Pharmaceuticals (CRBP) announced that the U.S. Food and Drug Administration has granted Fast Track designation to Resunab™ for the treatment of systemic sclerosis, or ...

DelveInsight’s Diffuse Cutaneous Systemic Sclerosis Market Insightsreport includes a comprehensive understanding of current treatment practices, emerging diffuse cutaneous systemic sclerosis drugs, ...